# Rehospitalisatie na intermitterend levosimendan bij gevorderd hartfalen: meta-analyse

*geplaatst 2017-11-01 · Hartfalen · ESC heart failure · doi 10.1002/ehf2.12177 · https://hartvaat.nl/2017/11/01/rehospitalisatie-na-intermitterend-levosimendan-bij-gevorderd-hartfalen-meta-ana/*

Meta-analyse van gerandomiseerde trials naar intermitterend levosimendan bij gevorderd hartfalen. Onderzoekt of herhaalde toediening ziekenhuisopnames vermindert.

## English: Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials.

This meta-analysis evaluated intermittent levosimendan administration in advanced heart failure, assessing whether repeated infusions improve quality of life and reduce rehospitalization in patients with refractory disease.

## Abstract (original, from the publication)

AIMS: Intermittent levosimendan administration has been suggested to improve survival in patients with advanced heart failure (AdHF). Quality of life is a key issue for AdHF patients and is negatively affected by frequent hospitalizations. METHODS AND RESULTS: CENTRAL, Google Scholar, MEDLINE/PubMed, Scopus, and the Cochrane Central Register of clinical trials (updated 15/1/2017) were searched for randomized controlled trials investigating the effect of intermittent levosimendan administration in patients with AdHF. The primary outcome was the number of patients requiring rehospitalization 3 months after the end of treatment. A total of 319 patients from six trials were included. Overall pooled analysis showed that the use of levosimendan was associated with a significant reduction in the number of rehospitalizations at 3 months: 33/207 (16%) vs. 39/113 (35%), risk ratio 0.40, 95% confidence interval 0.27-0.59, P < 0.001, I2  = 0%. This result was confirmed by sensitivity analyses. CONCLUSIONS: Within the limitations of this meta-analysis including also studies in which endpoints were not independently adjudicated and not clearly specified, repetitive or intermittent administration of levosimendan for patients with AdHF was associated with a reduction in the rehospitalization rate at 3 months. Large, high-quality randomized controlled trials are needed to confirm this finding.

Auteurs: Simona Silvetti, Alessandro Belletti, Antonella Fontana, Piero Pollesello

---
Bron: ESC heart failure, https://doi.org/10.1002/ehf2.12177. Bijgewerkt 2026-07-03T18:38:35Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.